
FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
A trio of experts will discuss the prospects of a handful of COVID-19 vaccine candidates which are entering phase 3 trials.
As the US death toll from the coronavirus pandemic rises above 146,000 and more than 4 million Americans have tested positive for the virus, the country waits anxiously for approval of a vaccine that will begin to bring the virulent spread under control.
This race for a vaccine will be the topic of the one-hour session featuring experts on viruses and vaccines.
The panel for this webinar features:






